GW Pharmaceuticals PLC- (NASDAQ:GWPH) shares fell 5.7% during mid-day trading on Wednesday . The company traded as low as $90.65 and last traded at $91.55, with a volume of 1,927,714 shares changing hands. The stock had previously closed at $97.10.

A number of brokerages have recently issued reports on GWPH. Leerink Swann reiterated a “buy” rating and issued a $130.00 price target on shares of GW Pharmaceuticals PLC- in a report on Tuesday, June 21st. Vetr cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating and set a $87.65 price objective for the company. in a research report on Wednesday, April 20th. Cantor Fitzgerald started coverage on GW Pharmaceuticals PLC- in a research report on Thursday, June 2nd. They issued a “buy” rating and a $181.00 price objective for the company. Piper Jaffray Cos. reissued a “buy” rating and issued a $147.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Sunday, June 26th. Finally, Goldman Sachs Group Inc. lowered their price objective on GW Pharmaceuticals PLC- from $135.00 to $105.00 in a research report on Tuesday, June 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. GW Pharmaceuticals PLC- presently has a consensus rating of “Buy” and a consensus price target of $124.92.

The company has a 50 day moving average price of $90.36 and a 200 day moving average price of $71.11. The stock’s market capitalization is $2.02 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.48. The company had revenue of $3.81 million for the quarter, compared to analysts’ expectations of $5.99 million. During the same period in the prior year, the company posted ($0.03) EPS. The firm’s revenue was down 58.3% compared to the same quarter last year. Equities analysts forecast that GW Pharmaceuticals PLC- will post ($4.23) earnings per share for the current year.

An institutional investor recently raised its position in GW Pharmaceuticals PLC- stock. Trexquant Investment LP increased its position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 188.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,719 shares of the biopharmaceutical company’s stock after buying an additional 15,509 shares during the period. Trexquant Investment LP owned approximately 0.11% of GW Pharmaceuticals PLC- worth $1,647,000 as of its most recent SEC filing.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.